MorphoSys
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 524
- Market Cap
- $2.8B
- Website
- http://www.morphosys.de
- Introduction
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Clinical Trials
71
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 3573
- Registration Number
- NCT04697160
- Locations
- 🇬🇧
MorphoSys Research Site, Westcliff-on-Sea, United Kingdom
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
- Conditions
- DLBCL
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- MorphoSys AG
- Registration Number
- NCT04300803
Lenalidomide Monotherapy in R/R DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 490
- Registration Number
- NCT04150328
- Locations
- 🇪🇸
MorphoSys Research Site, Salamanca, Spain
🇮🇹MorphoSys Research State, Novara, Italy
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 66
- Registration Number
- NCT04134936
- Locations
- 🇪🇸
MorphoSys Research Site, Vitoria-Gasteiz 1009, Spain
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- MorphoSys AG
- Target Recruit Count
- 24
- Registration Number
- NCT02639910
- Locations
- 🇬🇧
Clinical Study Site, Leeds, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
Molecular Partners Appoints Martin Steegmaier as Chief Scientific Officer to Advance DARPin Therapeutics Pipeline
Molecular Partners has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer effective October 1, 2025, bringing extensive oncology drug development experience from senior roles at Roche, MorphoSys, Boehringer Ingelberg, and SOTIO Biotech.
Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen
Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.
Maxion Therapeutics Strengthens Leadership with Appointment of Dr. Stefan Härtle as Chief Development Officer
Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.
Essential Thrombocythemia Market Set for Significant Growth as Novel Therapies Enter Pipeline
Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe.
TREMFYA Becomes First IL-23 Inhibitor to Reduce Structural Damage in Psoriatic Arthritis
Johnson & Johnson's TREMFYA (guselkumab) achieved both primary and secondary endpoints in Phase 3b APEX study, demonstrating significant reduction in symptoms and structural damage progression in active psoriatic arthritis at 24 weeks.
Knight Therapeutics Launches Minjuvi for Relapsed/Refractory DLBCL in Mexico
Knight Therapeutics has launched Minjuvi (tafasitamab) in Mexico for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplantation.
Biogen Initiates Phase 3 TRANSCEND Trial of Felzartamab for Late Antibody-Mediated Kidney Transplant Rejection
Biogen has begun dosing in the Phase 3 TRANSCEND study evaluating felzartamab against placebo in approximately 120 adult kidney transplant recipients with late antibody-mediated rejection (AMR).
Biopharma M&A Activity Reaches $79.4 Billion in 2024 Despite 50% Drop from Previous Year
Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year.
FDA Clears Novel Electronic Patch for Premature Ejaculation Treatment
Morari Medical's innovative MOR device, a drug-free patch using electrical stimulation to delay ejaculation, has received FDA clearance for improving sexual performance in adult males.
Novartis to Close MorphoSys Sites, Cut 330 Jobs Amid Pelabresib Development Challenges
Novartis announces closure of MorphoSys facilities in the US and Germany, affecting 330 jobs, following its $2.9 billion acquisition of the German biotech company.